Conv. Plasma
Nigella Sativa
Peg.. Lambda

All colchicine studies
Meta analysis
Home COVID-19 treatment researchColchicineColchicine (more..)
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta
Cannabidiol Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Ensovibep Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Peg.. Lambda Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Oxygen therapy -150% Improvement Relative Risk Hospitalization -150% Recovery 7% Case 1% Colchicine  Correa-Rodríguez et al.  Prophylaxis Is prophylaxis with colchicine beneficial for COVID-19? Retrospective 244 patients in Spain Study underpowered for serious outcomes Correa-Rodríguez et al., Medicina Clín.., Sep 2022 Favors colchicine Favors control

Clinical course of Covid-19 in a cohort of patients with Behçet disease

Correa-Rodríguez et al., Medicina Clínica (English Edition), doi:10.1016/j.medcle.2022.08.009
Sep 2022  
  Source   PDF   All Studies   Meta AnalysisMeta
Retrospective 244 Behçet disease patients in Spain, showing no significant difference in outcomes with colchicine treatment. Confounding by indication may significantly affect results - colchicine may be prescribed more often for more serious cases, which may have a higher baseline risk for COVID-19.
risk of oxygen therapy, 149.7% higher, RR 2.50, p = 1.00, treatment 1 of 163 (0.6%), control 0 of 81 (0.0%), continuity correction due to zero event (with reciprocal of the contrasting arm).
risk of hospitalization, 149.7% higher, RR 2.50, p = 1.00, treatment 1 of 163 (0.6%), control 0 of 81 (0.0%), continuity correction due to zero event (with reciprocal of the contrasting arm).
risk of no recovery, 7.1% lower, RR 0.93, p = 1.00, treatment 13 of 24 (54.2%), control 7 of 12 (58.3%), NNT 24, full recovery at 6 months.
risk of case, 0.6% lower, RR 0.99, p = 1.00, treatment 24 of 163 (14.7%), control 12 of 81 (14.8%), NNT 1100.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Correa-Rodríguez et al., 19 Sep 2022, retrospective, Spain, peer-reviewed, mean age 44.0, 6 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperColchicineAll
Clinical course of Covid-19 in a cohort of patients with Behçet disease
María Correa-Rodríguez, José-Luis Callejas-Rubio, Blanca Rueda-Medina, Raquel Ríos-Fernández, Javier De La Hera-Fernández, Norberto Ortego-Centeno
Medicina Clínica, doi:10.1016/j.medcli.2021.11.009
Objective: The implications of Covid-19 in patients with Behc ¸ et's disease (BD) are unknown. Patients with BD usually take long-term therapy with therapeutic agents that have been tested in Covid-19 patients. We aimed to assess the prevalence of Covid-19 in a cohort of patients with BD and investigate whether those patients with a long-term treatment with colchicine, tumor necrosis factor inhibitors (TNFi) or glucocorticoids are at reduced or increased prevalence of Covid-19 related clinical outcomes. Methods: A retrospective study was conducted among 244 patients with BD (86.1% females; mean age 43.95 ± 11.11 years). Each participant completed an online questionnaire regarding demographics, medical conditions, dispensed colchicine, TNFi or oral glucocorticoids, Covid-19 infection, clinical symptoms and recovery. Results: The prevalence of Covid-19 infection was 14.75%. Regarding dose of colchicine, the presence of ageusia was lower in patients taking 0.5 mg/day of colchicine compared to those taking 1.5 mg/day (p = 0.021). The prevalence of dyspnea was significantly higher in patients taking TNFi compared with those without therapy (p = 0.032). With regards to oral glucocorticoids, no significant differences were found. Conclusions: The prevalence of Covid-19 among patients with BD seems to be higher than that among the general population in Spain. Continuous TNFi therapy might increase the prevalence of worse clinical outcomes such as dyspnea; oral glucocorticoids and colchicine apparently provided no protection against the Covid-19 related clinical outcomes of patients with BD.
Authors' contributions Conceptualization, MCR, JLCR and NORC; Data curation, BRM, RFR and JHF; Formal analysis, MCR and NOC; Methodology, MCR, BRM, NOC; Project administration, MCR and JFH; Supervision, JLCR and NOC; Validation, BRM and RRF; Visualization, BRM and JHF; Writing -original draft, MCR; Writing -review & editing, BRM and NOC. All authors read and approved the final manuscript. Ethical conduct of research All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Written informed consent was obtained for all participants. Conflicts of interest The authors declare no conflict of interest. Appendix
Bourguiba, Delplanque, Vinit, Ackermann, Savey et al., Clinical course of COVID-19 in a cohort of 342 familial Mediterranean fever patients with a long-term treatment by colchicine in a French endemic area, Ann Rheum Dis, doi:10.1136/annrheumdis-2020-218707
Cheng, Li, Cui, Chen, Shan et al., Efficacy and safety of corticosteroid treatment in patients with COVID-19: a systematic review and meta-analysis, Front Pharmacol, doi:10.3389/fphar.2020.571156
Cure, Kucuk, Cure, Colchicine may not be effective in COVID-19 infection; it may even be harmful?, Clin Rheumatol, doi:10.1007/s10067-020-05144-x
Dursun, Temiz, Özer, Daye, Ataseven, Management of patients with Behc ¸ et's disease during the COVID-19 pandemic, Dermatol Ther, doi:10.1111/dth.14063
Elmas, Demirbas, Bagcıer, Türsen, Atasoy et al., Treatment considerations for Behc ¸ et disease in the era of COVID-19: a narrative review, Dermatol Ther, doi:10.1111/dth.14507
Espinosa, Araujo, Amaro, Bodro, Moreno et al., COVID-19 and Behc ¸ et's disease: clinical case series, Ann Rheum Dis, doi:10.1136/annrheumdis-2020-217778
Feldmann, Maini, Woody, Holgate, Winter et al., Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed, Lancet, doi:10.1016/S0140-6736(20)30858-8
Gendelman, Amital, Luigi, Watad, Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2: insights from a large healthcare database analysis, Autoimmun Rev, doi:10.1016/j.autrev.2020.102566
Gianfrancesco, Hyrich, Hyrich, Al-Adely, Al-Adely et al., Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry, Ann Rheum Dis
Haberman, Axelrad, Chen, Castillo, Yan et al., Covid-19 in immune-mediated inflammatory diseases-case series from New York, N Engl J Med, doi:10.1056/NEJMc2009567
Han, Jiang, Xia, He, Lv et al., COVID-19 in a patient with long-term use of glucocorticoids: a study of a familial cluster, Clin Immunol, doi:10.1016/j.clim.2020.108413
Hatemi, Christensen, Bang, Bodaghi, Celik et al., update of the EULAR recommendations for the management of Behc ¸ et's syndrome, Ann Rheum Dis, doi:10.1136/annrheumdis-2018-213225
Kobak, COVID-19 infection in a patient with FMF: does colchicine have a protective effect, Ann Rheum Dis, doi:10.1136/annrheumdis-2020-217882
Leccese, Alpsoy, Behc ¸ et's disease: an overview of etiopathogenesis, Front Immunol, doi:10.3389/fimmu.2019.01067
Ledford, Coronavirus breakthrough: dexamethasone is first drug shown to save lives, Nature
Lopes, Bonjorno, Giannini, Amaral, Menezes et al., Beneficial effects of colchicine for moderate to severe COVID-19: a randomised, double-blinded, placebo-controlled clinical trial, RMD Open, doi:10.1136/rmdopen-2020-001455
Mancinelli, Bassi, Salcuni, Predisposing and motivational factors related to social network sites use: systematic review, JMIR Form Res, doi:10.2196/12248
Montealegre-Gómez, Garavito, Gómez-López, Rojas-Villarraga, Parra-Medina, Colchicine: a potential therapeutic tool against COVID-19. Experience of 5 patients, Reumatol Clin, doi:10.1016/j.reuma.2020.05.001
Montero, Martínez-Barrio, Serrano-Benavente, González, Rivera et al., Coronavirus disease 2019 (COVID-19) in autoimmune and inflammatory conditions: clinical characteristics of poor outcomes, Rheumatol Int, doi:10.1007/s00296-020-04676-4
Pelechas, Drossou, Voulgari, Drosos, Anti-rheumatic drugs for the fight against the novel coronavirus infection (SARSCoV-2): what is the evidence?, Mediterr J Rheumatol, doi:10.31138/mjr.31.3.259
Sandhu, Tieng, Chilimuri, Franchin, A case control study to evaluate the impact of colchicine on patients admitted to the hospital with moderate to severe covid-19 infection, Can J Infect Dis Med Microbiol, doi:10.1155/2020/8865954
Scarsi, Piantoni, Colombo, Airó, Richini et al., Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome, Ann Rheum Dis, doi:10.1136/annrheumdis-2020-217712
Schlesinger, Firestein, Brunetti, Colchicine in COVID-19: an old drug new use, Curr Pharmacol Rep, doi:10.1007/s40495-020-00225-6
Singh, Majumdar, Singh, Misra, Role of corticosteroid in the management of COVID-19: a systemic review and a Clinician's perspective, Diabetes Metab Syndr Clin Res Rev, doi:10.1016/j.dsx.2020.06.054
Tong, Liu, Xiao, Su, Immunopathogenesis of Behcet's disease, Front Immunol, doi:10.3389/fimmu.2019.00665
Vivanco-Hidalgo, Molina, Martinez, Ñas, Sánchez-Montalvá et al., Incidence of COVID-19 in patients exposed to chloroquine and hydroxychloroquine: results from a population-based prospective cohort in Catalonia. Spain, Euro Surveill, doi:10.2807/1560-7917.ES.2021.26.9.2001202
Vrachatis, Giannopoulos, Giotaki, Raisakis, Kossyvakis et al., Impact of colchicine on mortality in patients with COVID-19: a meta-analysis, Hell J Cardiol, doi:10.1016/j.hjc.2020.11.012.S1109-9666(20)30285-2
Wang, Liu, Shao, Xiaopeng, Su et al., Risk and clinical outcomes of COVID-19 in patients with rheumatic diseases compared with the general population: a systematic review and meta-analysis, Rheumatol Int, doi:10.1007/s00296-021-04803-9
Yousaf, Gayam, Feldman, Zinn, Kolodney, Clinical outcomes of COVID-19 in patients taking tumor necrosis factor inhibitors or methotrexate: a multicenter research network study, J Am Acad Dermatol, doi:10.1016/j.jaad.2020.09.009
Yurttas, Oztas, Tunc, Balkan, Tabak et al., Characteristics and outcomes of Behc ¸ et's syndrome patients with Coronavirus Disease 2019: a case series of 10 patients, Intern Emerg Med, doi:10.1007/s11739-020-02427-8
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop